Navigation Links
Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy

Recent research, which appears in the current issue of Diabetes Care, establishes Ruboxistaurin as a promising novel treatment that may improve upon established therapies for diabetic nephropathy//.

Nephropathy is known to develop in 40% of people with type 2 diabetes and is the leading cause of end-stage renal disease in the U.S. and the developed world.

Many persons with diabetes have progressive nephropathy even with the established therapies. Therefore, treatments targeting novel pathogenic mechanisms may be beneficial.

Studies have shown an important role for protein kinase C (PKC)-? in the pathogenesis of diabetic nephropathy. Ruboxistaurin selectively inhibits protein kinase C-? and ameliorates kidney disease in animal models of diabetes.

The study was performed to evaluate the effects of 32mg/day ruboxistaurin for 1 year in persons with type 2 diabetes and persistent albuminuria persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) was also calculated.

It was found that after one year, urinary ACR decreased significantly in participants treated with ruboxistaurin and nonsignificantly in the placebo group. The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over 1 year.

Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences.

The study authors conclude that ruboxistaurin had favorable effects on albuminuria and renal function in persons with type 2 diabetes and nephropathy. The albuminuria-lowering effect occurred early and was sustained long term. Those treated with ruboxista urin did not experience a significant decline in renal function. Ruboxistaurin may thus add benefit to established therapies for diabetic nephropathy. The authors suggest that large-scale trials should be performed to confirm its effectiveness and safety.
'"/>




Related medicine news :

1. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
2. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
3. Novel biopsy technique for prostate cancer
4. Novel computer model for breast cancer
5. Novel research on liver cancer
6. Novel way to fight cancer
7. Novel test for bowel cancer
8. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
9. Novel Therapy for Chronic Problem
10. Blood Sugar Kept In Control By Novel Protein
11. Novel antibiotic dressing developed for improved wound healing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, ... entry through labeling, storing, shipping and disposal. The new version is a faster ...
(Date:12/2/2016)... West Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Norway, Nothing Water has some unique properties including its unmatched natural purity of just ... described as clean and crisp. , Nothing Water has been available in several ShopRite ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility ... designated as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence ... “It’s an honor to be designated a Cigna Infertility Center of Excellence," said ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
(Date:11/30/2016)... Nov. 30, 2016  Millennium Dental Technologies, Inc. announced that ... the Superior Court of the State of California ... violation of the California,s Uniform Trade ... and fraudulent business practices which are untrue and misleading, as ... This is the second time in three years that ...
Breaking Medicine Technology: